Affingery, a spinout from Duke University, has secured more than $3 million in new federal grants.

Among the grants is a $2.05 million Phase 2 Small Business Innovation Research grant from the National Institutes of Health.

Affinergy uses technology licensed from Duke to create what it calls "biofriendly linkers" that work between body systems and proteins, drugs, cells or biomaterials to "kick start" a healing or therapeutic process. The linkers are used as coatings.

The Phase 2 grant is for a program designed to use “linkers: to speed up a patient’s healing process. The National Institute of General Medical Sciences at NIH made the award.

The other four grants are Phase 1 awards and total more than $1 million, according to Affinergy.

"We are anxious to initiate the Phase 2 activities and accelerate the pathway to commercialization," said Shrikumar Nair, Affinergy’s principal investigator for the phase two award. He also is head of discovery chemistry at Affinergy.

"We have achieved great momentum with this program and are excited by the potential to improve the clinical performance of a number of different products,” he added. “This program could provide a significant clinical benefit for a large number of patients."